Inhibition of FGFR3-BAIAP2L1 fusion kinase oncogenic potential by CH5183284/Debio 1347, a compound that inhibits FGFR3 kinase activity constitutively activated by BAIAP2L1 BAR domain dimerization

N. Akiyama (1), Y. Nakanishi (1), T. Tsukaguchi (1), Y. Satoh(1), Y. Nagata (1), T. Takahashi (2), Y. Nishito (1), M. Ashihara (1), N. Ishii (1), M. Aoki (1)

Abstract – Presented at AACR 2014, San Diego, CA, USA

1. Chugai Pharmaceutical Co.,Ltd., Kanagawa, Japan
2. Chugai Research Institute for Medical Science, Inc., Kanagawa, Japan